2639 Results

People

  1. Zelenetz
    Zelenetz
  2. Horwitz
    Horwitz
  3. Palomba
    Palomba
  4. Noy
    Noy
  5. Moskowitz
    Moskowitz
  6. Younes
    Younes
  7. Matasar
    Matasar
  8. Moskowitz
    Moskowitz
  9. Yahalom
    Yahalom
  10. Portlock
    Portlock

Groups

  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)
  7. Executive Committee, Center for Hematologic Malignancies (389)
  8. Epidemiology and Biostatistics (363)
  9. GSK Faculty (356)
  10. Department of Pathology and Laboratory Medicine (300)
  1. "Lymphoma"
Formats
  1. Meeting Abstract (1340)
  2. Journal Article (1048)
  3. Book Section (63)
  4. Review (63)
  5. Editorial (37)
  6. Research Letter (35)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)

More Groups

People
  1. Andrew Zelenetz (767)
  2. Steven Horwitz (645)
  3. Maria Palomba (415)
  4. David Straus (356)
  5. Ariela Noy (351)
  6. Alison Moskowitz (339)

More People

Years
  1. 2025 (28)
  2. 2024 (100)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (833)
  2. Journal of Clinical Oncology (274)
  3. Hematological Oncology (110)
  4. Leukemia and Lymphoma (81)
  5. British Journal of Haematology (79)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (898)
  2. American Society of Clinical Oncology (290)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (173)
  5. John Wiley & Sons (95)
  6. Nature Publishing Group (92)

More Publishers

Results (2639)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Management of transaminase elevations in patients receiving idelalisib
    Meeting Abstract

    Wierda, W. G.; Coutre, S.; Flinn, I.; Gopal, A. K.; O'Brien, S. M.; Salles, G. A.; Zelenetz, A. D.; Newcomb, T.; Waldapfel, C. C.; Ye, W.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • An evaluation of the chronic lymphocytic leukemia (CLL) international prognostic index as a prognostic tool in patients with relapsed/refractory CLL in idelalisib phase 3 randomized studies
    Meeting Abstract

    Soumerai, J. D.; Barrientos, J. C.; Hallek, M.; Kipps, T. J.; Jones, J. A.; Stilgenbauer, S.; Xing, G.; Yao, N. S.; Ysebaert, L.; Zelenetz, A. D.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Pre-cancer cardiovascular risk factors and anthracycline-related cardiotoxicity among non-Hodgkin lymphoma survivors
    Meeting Abstract

    Salz, T.; Brown, P.; Zabor, E. C.; Dalton, S. O.; Raghunathan, N. J.; Matasar, M. J.; Steingart, R.; Vickers, A. J.; Oeffinger, K. C.; Johansen, C.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Differences between Japan and rest of world (ROW) in disease presentation and outcome of previously treated adult T-cell leukemia-lymphoma (ATL) using therapy with a monoclonal antibody to CCR4, mogamulizumab (moga)
    Meeting Abstract

    Phillips, A. A.; Horwitz, S. M.; Taylor, G. P.; Humphrey, J. S.; Tobinai, K.; Ishida, T.; Ueda, R.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Cerdulatinib (PRT062070): A dual SYK/JAK inhibitor in patients with relapsed/refractory b-cell malignancies - Pharmacokinetic and pharmacodynamic outcomes with twice-daily (BID) vs once-daily (QD) dosing
    Meeting Abstract

    Hamlin, P. A.; Flinn, I.; Wagner-Johnston, N.; Burger, J.; Michelson, G.; Pandey, A.; Birrell, M.; Coffey, G.; Leeds, J.; Sabalvaro-Torres, A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Metabolic tumor volume to predict event free survival in patients with relapsed/refractory HL treated with brentuximab vedotin-based salvage therapy
    Meeting Abstract

    Gavane, S. C.; Ito, K.; Moskowitz, C. H.; Moskowitz, A. J.; Schoder, H.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Results of a randomized, double-blind placebo controlled phase 3 study evaluating idelalisib in combination with bendamustine and rituximab in patients with relapsed/refractory CLL and adverse prognostic features
    Meeting Abstract

    Barrientos, J. C.; Brown, J. R.; Atallah, E. L.; Coutre, S.; De La Serna, J.; Eradat, H. A.; Farber, C. M.; Janssens, A.; Loscertales, J.; Pocock, C.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A phase 1/2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas (NHLs)
    Meeting Abstract

    Armand, P.; Brody, J.; Barr, P. M.; Shustov, A. R.; Moskowitz, A. J.; Kline, J. P.; Savage, K. J.; Kuruvilla, J.; Josephson, N. C.; Zinzani, P. L.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Assessing the potential for enhanced antibody-dependent cellmediated cytotoxicity (ADCC) by combining the CD137 antibody urelumab with rituximab or cetuximab in patients with refractory lymphoma or select advanced solid tumors
    Meeting Abstract

    Segal, N. H.; Sharma, M.; Le, D. T.; Ott, P. A.; Ferris, R. L.; Zelenetz, A. D.; Neelapu, S. S.; Levy, R.; Lossos, I. S.; Jacobson, C.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma: CALGB/Alliance 50303
    Meeting Abstract

    Wilson, W. H.; Sin-Ho, J.; Pitcher, B. N.; Hsi, E. D.; Friedberg, J.; Cheson, B.; Bartlett, N. L.; Smith, S.; Johnston, N. W.; Kahl, B. S.; more...
    Blood (2016)

    Fulltext@MSK | Save